Get to know our clinical trials
Randomized, double-blind, placebo-controlled proof-of-concept (PoC) study to evaluate the efficacy, safety and tolerability of itepekimab in participants with inadequately controlled chronic rhinosinusitis without nasal polyps.
THE MAIN OBJECTIVE OF THIS STUDY IS TO TEST THE EFFECTS OF ITEPEKIMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITHOUT NASAL POLYPS WHO ARE ALREADY USING CORTICOSTEROID NASAL SPRAYS.
Specialist
Otorhinolaryngology Department
Navarre headquarters
Status
In recruitment
headquarters
Pamplona
Technical Summary
- RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PROOF-OF-CONCEPT (POC) STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ITEPEKIMAB IN PARTICIPANTS WITH INADEQUATELY CONTROLLED CHRONIC RHINOSINUSITIS WITHOUT NASAL POLYPS.
- Code EudraCT: 2024-515576-12
- Protocol number: ACT18421
- Promoter: Sanofi-Aventis Recherche & Développement
- Molecule/Drug: itepekimab
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.